Renal failure associated with cancer and its treatment: An update

Journal of the American Society of Nephrology

Volumn 16, Issue 1, 2005, Pages 151-161

  Humphreys, Benjamin D ^a   Soiffer, Robert J ^b   Magee, Colm C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CISPLATIN; CYCLOSPORIN; DEFIBROTIDE; FLUOROURACIL; GEMCITABINE; GLUCOCORTICOID; MITOMYCIN C; PAMIDRONIC ACID; TACROLIMUS;

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; BONE METASTASIS; CANCER; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; GLOMERULOPATHY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERCALCEMIA; KIDNEY PARENCHYMA; KIDNEY TUBULE DISORDER; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR CELL; TUMOR LYSIS SYNDROME; URIC ACID NEPHROPATHY; VEIN OCCLUSION; NEOPLASM;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY FAILURE, ACUTE; NEOPLASMS;

EID: 21644478279     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004100843     Document Type: Review

References (122)

1. Kapoor M, Chan GZ: Malignancy and renal disease. Crit Care Clin 17: 571-598, viii, 2001
2. da Silva J, Mesler D. Acute renal failure as a result of malignancy. In: Acute Renal Failure: A Companion to Brenner and Rector's The Kidney, edited by Molitoris B, Finn W, Indianapolis, Harcourt, 2001, pp 312-321
3. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158: 1889-1893, 1998
4. U.S. Renal Data System. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2003
5. Murphy SW, Barrett BJ, Parfrey PS: Contrast nephropathy. J Am Soc Nephrol 11: 177-182, 2000
6. Thomas MH, Chisholm GD: Retroperitoneal fibrosis associated with malignant disease. Br J Cancer 28: 453-458, 1973
7. Wu J, Catalano E, Coppola D: Retroperitoneal fibrosis (Ormond's disease): Clinical pathologic study of eight cases. Cancer Control 9: 432-437, 2002
8. Coggins CH: Renal failure in lymphoma. Kidney Int 17: 847-855, 1980
9. Xiao JC, Walz-Mattmuller R, Ruck P, Horny HP, Kaiserling E: Renal involvement in myeloproliferative and lymphoproliferative disorders. A study of autopsy cases. Gen Diagn Pathol 142: 147-153, 1997
10. Richmond J, Sherman RS, Diamond HD, Craver LF: Renal lesions associated with malignant lymphomas. Am J Med 32: 184-207, 1962
11. Tornroth T, Heiro M, Marcussen N, Franssila K: Lymphomas diagnosed by percutaneous kidney biopsy. Am J Kidney Dis 42: 960-971, 2003
12. Obrador GT, Price B, O'Meara Y, Salant DJ: Acute renal failure due to lymphomatous infiltration of the kidneys. J Am Soc Nephrol 8: 1348-1354, 1997
13. Wagle DG, Moore RH, Murphy GP: Secondary carcinomas of the kidney. J Urol 114: 30-32, 1975
14. Manning EC, Belenko MI, Frauenhoffer EE, Ahsan N: Acute renal failure secondary to solid tumor renal metastases: Case report and review of the literature. Am J Kidney Dis 27: 284-291, 1996
15. Jeha S: Tumor lysis syndrome. Semin Hematol 38[Suppl 10]: 4-8, 2001
16. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116: 546-554, 2004
17. Conger JD: Acute uric acid nephropathy. Med Clin North Am 74: 859-871, 1990
18. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 33: 225-234, 1999
19. Jerome KR, Corey L: The danger within. N Engl J Med 350: 411-412, 2004
20. Boles JM, Dutel JL, Briere J, Mialon P, Robasckiewicz M, Garre M: Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53: 2425-2429, 1984
21. Zager RA: Hyperphosphatemia: A factor that provokes severe experimental acute renal failure. J Lab Clin Med 100: 230-239, 1982
22. Altman A: Acute tumor lysis syndrome. Semin Oncol 28[Suppl 5]: 3-8, 2001
23. Frei E 3rd, Bentzel CJ, Rieselbach R, Block JB: Renal complications of neoplastic disease. J Chron Dis 16: 757-776, 1963
24. Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ: Hyperuricemic acute renal failure. Arch Intern Med 133: 349-359, 1974
25. Cairo MS, Bishop M: Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol 127: 3-11, 2004
26. Razis E, Arlin ZA, Ahmed T, Feldman EJ, Puccio C, Cook P, Chun HG, Helson L, Mittelman A: Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol 91: 171-174, 1994
27. Hande KR, Hixson CV, Chabner BA: Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 41: 2273-2279, 1981
28. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, Little AS: Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 283: 354-357, 1970
29. Ablin A, Stephens BG, Hirata T, Wilson K, Williams HE: Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 21: 771-778, 1972
30. Ronco C, Bellomo R, Inguaggiato P, Bonello M, Bordoni V, Salvatori G, D'Intini V, Ratanarat R: Rasburicase therapy in acute hyperuricemic renal dysfunction. Contrib Nephrol 144: 158-165, 2004
31. Patte C, Sakiroglu O, Sommelet D: European experience in the treatment of hyperuricemia. Semin Hematol 38[Suppl 10]: 9-12, 2001
32. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97: 2998-3003, 2001
33. Pui CH, Jeha S, Irwin D, Camitta B: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15: 1505-1509, 2001
34. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21: 4402-4406, 2003
35. Leach M, Parsons RM, Reilly JT, Winfield DA: Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 20: 169-172, 1998
36. Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RA: Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 34: E20, 1999
37. van den Berg H, Reintsema AM: Renal tubular damage in rasburicase: Risks of alkalinisation. Ann Oncol 15: 175-176, 2004
38. Maesaka JK, Mittal SK, Fishbane S: Paraneoplastic syndromes of the kidney. Semin Oncol 24: 373-381, 1997
39. Appel GB, Radhakrishnan J, D'Agati, V. Secondary glomerular disease. In: The Kidney, edited by Brenner BM, Philadelphia, W.B. Saunders Company, 2000, pp 1350-1449
40. Eagen JW: Glomerulopathies of neoplasia. Kidney Int 11: 297-303, 1977
41. Alpers CE, Cotran RS: Neoplasia and glomerular injury. Kidney Int 30: 465-473, 1986
42. Ziakas PD, Giannouli S, Psimenou E, Nakopoulou L, Voulgarelis M: Membranous glomerulonephritis in chronic lymphocytic leukemia. Am J Hematol 76: 271-274, 2004
43. Da'as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, Goldfarb AW, Ben-Yehuda D: Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: A retrospective study in 700 patients. Eur J Haematol 67: 158-164, 2001
44. Jefferson JA, Couser WG: Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 23: 400-405, 2003
45. Burstein DM, Korbet SM, Schwartz MM: Membranous glomerulonephritis and malignancy. Am J Kidney Dis 22: 5-10, 1993
46. Cahen R, Francois B, Trolliet P, Gilly J, Parchoux B: Aetiology of membranous glomerulonephritis: A prospective study of 82 adult patients. Nephrol Dial Transplant 4: 172-180, 1989
47. Row PG, Cameron JS, Turner DR, Evans DJ, White RH, Ogg CS, Chantler C, Brown CB: Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 44: 207-239, 1975
48. Couser WG, Wagonfeld JB, Spargo BH, Lewis EJ: Glomerular deposition of tumor antigen in membranous nephropathy associated with colonic carcinoma. Am J Med 57: 962-970, 1974
49. Helin H, Pasternack A, Hakala T, Penttinen K, Wager O: Glomerular electron-dense deposits and circulating immune complexes in patients with malignant tumours. Clin Nephrol 14: 23-30, 1980
50. Robinson WL, Mitas JA 2nd, Haerr RW, Cohen IM: Remission and exacerbation of tumor-related nephrotic syndrome with treatment of the neoplasm. Cancer 54: 1082-1084, 1984
51. Pankhurst T, Savage CO, Gordon C, Harper L: Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 43: 1532-1535, 2004
52. Edgar JD, Rooney DP, McNamee P, McNeill TA: An association between ANCA positive renal disease and malignancy. Clin Nephrol 40: 22-25, 1993
53. Knight A, Askling J, Ekbom A: Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 100: 82-85, 2002
54. Moake JL: Thrombotic microangiopathies. N Engl J Med 347: 589-600, 2002
55. George JN, Selby GB: Thrombotic microangiopathy after allogeneic bone marrow transplantation: A pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant 33: 1073-1074, 2004
56. Halevy D, Radhakrishnan J, Markowitz G, Appel G: Thrombotic microangiopathies. Crit Care Clin 18: 309-320, vi, 2002
57. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60: 831-846, 2001
58. Kwaan HC, Gordon LI: Thrombotic microangiopathy in the cancer patient. Acta Haematol 106: 52-56, 2001
59. Lohrmann HP, Adam W, Heymer B, Kubanek B: Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 79: 368-375, 1973
60. Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP: Microangiopathic hemolytic anemia and cancer: A review. Medicine (Baltimore) 58: 377-384, 1979
61. Murgo AJ: Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 24: 161-177, 1987
62. Valavaara R, Nordman E: Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 55: 47-50, 1985
63. Medina PJ, Sipols JM, George JN: Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8: 286-293, 2001
64. Eli Lilly and Company: Annual Report, Indianapolis, Eli Lilly, 2003
65. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85: 2023-2032, 1999
66. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F: Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 33: 555-562, 1999
67. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, Zhu AX, Magee CC: Gemcitabine-associated thrombotic microangiopathy. Cancer 100: 2664-2670, 2004
68. Morel-Maroger L, Kanfer A, Solez K, Sraer JD, Richet G: Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): Clinicopathologic study in 20 adults. Kidney Int 15: 548-558, 1979
69. Remuzzi G, Ruggenenti P, Bertani, T. Thrombotic microangiopathy. In: Renal Pathology, edited by Tisher CC, Philadelphia, Lippincott, 1994, pp 1154-1184
70. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493, 1996
71. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846-854, 1999
72. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21: 389-406, 1999
73. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164-1172, 2001
74. Kunin M, Kopolovic J, Avigdor A, Holtzman EJ: Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 19: 723-726, 2004
75. D'Agati V, Suh JI, Carbone L, Cheng JT, Appel G: Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study. Kidney Int 35: 1358-1370, 1989
76. Markowitz GS, Fine PL, D'Agati VD: Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39: 1118-1122, 2002
77. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281-289, 2003
78. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D: Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41: E18, 2003
79. Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z: Pamidronate-induced nephrotoxic tubular necrosis-A case report. Clin Nephrol 61: 63-67, 2004
80. Safirstein RL. Renal diseases induced by antineoplastic agents. In: Diseases of the Kidney and Urinary Tract, edited by Schrier RW, Philadelphia, Lippincott, 2001, pp 1175-1188
81. Loberiza F: Report on state of the art in blood and marrow transplantation. Int Bone Marrow Transpl Registry News 10: 1-12, 2003
82. Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED: Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 13: 210-216, 1989
83. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan AA, Czuczman MS, Slack J, Wetzler M, Mookerjee BK, Silva J, McCarthy PL Jr: Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 32: 405-410, 2003
84. Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J, Slat-Vasquez V, Shpall EJ, Jones RB, Bearman SI, Schrier RW: Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 62: 566-573, 2002
85. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW: Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 50: 1026-1031, 1996
86. Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG, Maris MB, Nieto Y, Edelstein CL, Schrier RW, McSweeney P: Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 15: 1868-1876, 2004
87. Noel C, Hazzan M, Noel-Walter MP, Jouet JP: Renal failure and bone marrow transplantation. Nephrol Dial Transplant 13: 2464-2466, 1998
88. Zager RA: Acute renal failure in the setting of bone marrow transplantation. Kidney Int 46: 1443-1458, 1994
89. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G, Bonfichi M, Pagnucco G, Salvaneschi L, Bernasconi C: Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 23: 607-612, 1999
90. Smith DM, Weisenburger DD, Bierman P, Kessinger A, Vaughan WP, Armitage JO: Acute renal failure associated with autologous bone marrow transplantation. Bone Marrow Transplant 2: 195-201, 1987
91. Ayello J, Hesdorffer C, Reiss RF: A semiautomated technique for volume reduction of stem cell suspensions for autotransplantation. J Hematother 4: 545-549, 1995
92. Kumar S, DeLeve LD, Kamath PS, Tefferi A: Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 78: 589-598, 2003
93. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118: 255-267, 1993
94. Wadleigh M, Ho V, Momtaz P, Richardson P: Hepatic veno-occlusive disease: Pathogenesis, diagnosis and treatment. Curr Opin Hematol 10: 451-462, 2003
95. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA: Marked enzymuria after bone marrow transplantation: A correlate of veno-occlusive disease-induced "hepa-torenal syndrome." J Am Soc Nephrol 6: 1655-1660, 1995
96. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92: 3599-3604, 1998
97. El-Seisi S, Gupta R, Clase CM, Forrest DL, Milandinovic M, Couban S: Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 9: 683-688, 2003
98. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC: Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100: 4337-4343, 2002
99. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T: Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 111: 1122-1129, 2000
100. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Comely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391-1402, 2004
101. Davenport A: Is there a role for continuous renal replacement therapies in patients with liver and renal failure? Kidney Int Suppl 72: S62-S66, 1999
102. Cohen EP: Renal failure after bone-marrow transplantation. Lancet 357: 6-7, 2001
103. Cohen EP, Hussain S, Moulder JE: Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys 55: 190-193, 2003
104. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH: Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10: 328-336, 2004
105. Cohen EP, Robbins ME: Radiation nephropathy. Semin Nephrol 23: 486-499, 2003
106. Cohen EP: Radiation nephropathy after bone marrow transplantation. Kidney Int 58: 903-918, 2000
107. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, Keller A, Kurtz JM, Chapuis B: Renal toxicity after allogeneic bone marrow transplantation: The combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 14: 579-585, 1996
108. Lawton CA, Barber-Derus SW, Murray KJ, Cohen EP, Ash RC, Moulder JE: Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. Int J Radiat Oncol Biol Phys 23: 681-686, 1992
109. Juckett MB, Cohen EP, Keever-Taylor CA, Zheng Y, Lawton CA, Moulder JE, Klein J: Loss of renal function following bone marrow transplantation: An analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors. Bone Marrow Transplant 27: 451-456, 2001
110. Lawton CA, Fish BL, Moulder JE: Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation. Int J Radiat Oncol Biol Phys 28: 883-889, 1994
111. Henry NL, Li S, Kim HT, Magee C, Alyea E, Ho V, Lee S, Soiffer R, Antin JH, Cutler C: Sirolimus and thrombotic microangiopathy after allogeneic stem cell transplantation. J Am Soc Nephrol 15: 578A, 2004
112. Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management. Cancer 101: 1936-1946, 2004
113. Magee C, Pascual M: The growing problem of chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 994-996, 2003
114. Myers BD, Newton L: Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 2[Suppl 1]: S45-S52, 1991
115. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55: 2457-2466, 1999
116. Young BA, Marsh CL, Alpers CE, Davis CL: Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 28: 561-571, 1996
117. Eknoyan G: Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis 41[Suppl]: 3-10, 2003
118. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592, 2004
119. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: A diagnostic dilemma. Transfusion 44: 294-304, 2004
120. Cohen EP, Piering WF, Kabler-Babbitt C, Moulder JE: End-stage renal disease (ESRD) after bone marrow transplantation: Poor survival compared to other causes of ESRD. Nephron 79: 408-412, 1998
121. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL: Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 114: 954-955, 1991
122. Gruss E, Bernis C, Tomas JF, Garcia-Canton C, Figuera A, Motellon JL, Paraiso V, Traver JA, Fernandez-Ranada JM: Acute renal failure in patients following bone marrow transplantation: Prevalence, risk factors and outcome. Am J Nephrol 15: 473-479, 1995